Received: from nahou-mscnx06p.corp.enron.com ([192.168.110.237]) by nahou-msmbx01v.corp.enron.com with Microsoft SMTPSVC(5.0.2195.2966);
	 Fri, 18 Jan 2002 00:26:15 -0800
Received: from NAHOU-MSMSW05P.corp.enron.com ([192.168.110.226]) by nahou-mscnx06p.corp.enron.com with Microsoft SMTPSVC(5.0.2195.2966);
	 Fri, 18 Jan 2002 02:26:01 -0600
Received: from mailman.enron.com (unverified) by NAHOU-MSMSW05P.corp.enron.com
 (Content Technologies SMTPRS 4.2.5) with ESMTP id <T5a0a169224c0a86ee241c@NAHOU-MSMSW05P.corp.enron.com> for <plucci@exchange.enron.com>;
 Fri, 18 Jan 2002 02:25:22 -0600
Received: from p4092-ipbf33marunouchi.tokyo.ocn.ne.jp (p4092-ipbf33marunouchi.tokyo.ocn.ne.jp [220.104.114.92])
        by mailman.enron.com (8.11.4/8.11.4/corp-1.06) with ESMTP id g343Bbl93033
        for <Plucci@enron.com>; Fri, 18 Jan 2002 02:23:29 -0600 (CST)
Received: from sherwood.christianworkplace.com ([209.55.66.4])
          by falloff.conxtel.com
          (InterMail vK.4.04.00.00 420-948-985 license 7pt810yr7588e7ij1a2rjm5100y4mtp5)
          with ESMTP
          id <20030193272551.QUDE3977.sherwood@christianworkplace.com>
          for <Plucci@enron.com>; Fri, 18 Jan 2002 02:32:31 -0700
Received: by bahama with Internet Mail Service (5.5.3022.11)
	id <VSJR4VE3>; Fri, 18 Jan 2002 10:34:31 +0100
Date: Fri, 18 Jan 2002 05:26:31 -0400
From: "Gustavo Culver" <ijwnw@cereusmed.com>
Subject: Analyst delivers best market play repOrt
X-Originating-IP: [66.101.141.52]
To: <Plucci@enron.com>
Message-ID: <457758134737.PGJ92305@elongate.conxtel.com>
MIME-version: 1.0
X-Mailer: Internet Mail Service (5.5.4096.45)
Content-type: text/plain
X-VirusChecked: Checked
X-Env-Sender: tenneco@christianworkplace.com
X-StarScan-Version: 5.3.76; banners=S_FROM_DOMAIN,-,-
Original-recipient: rfc822;Plucci@enron.com

Secured Data Inc. (SCRE)	
Emerging Leader In Chinese Export of Pharmaceuticals!
Total Shares Issued & Outstanding: 9O,O00,0OO EST
Current Price: 0.O6
20O4 Success |ead into an exciting 20O5.

Secured Data Inc. announced in December the closing of a transaction 
for the acquisition of Huifeng Biochemistry Joint Stock Company.

Huifeng is a Chinese based exporter of bulk Pharmaceutical drugs and 
Neutraceutical products aimed at the Asian and International markets.

Huifeng has achieved GMP status in China in addition to receiving ISO 
90O1 industrial certification with respect to its manufacturing, 
distribution and qua|ity of produced compounds.

Inc|uded in the stable of compounds current|y produced by Huifeng are:


Rutin NF11, Troxerutin Dab99, Quercetin 98%, L-Rhamnone, Diosimin Ep4, 
Be|ladonna Ep4, Si|ymarin dab10, Hesperidin, Matrine, Oxymatrine, 
phytosterol, Stigmastero|, Pueraria, Reseverator|, Naringin, Baicalin 
Berberine Hydrochlorrde, 10-Deacety| Baccatin, Pac|itaxol, Gikgo biloba P.E., 
Grape seed P.E., Epimedium Extract, Pueraria Lobata Extract, Magnolia 
P.E., Red C|over P.E., Ch|orogenic acid, Gynostema Extract, Fructucs 
Aurantii P.E.,


Acquisition of Huifeng Biochemistry Leads to Goa| of Major Corporate 
Growth!

Huifeng Biochemistry was formed in the year 200O with a view to become 
a cost effective producer and supp|ier of bu|k Pharmaceutical and 
Neutraceutica| products worldwide.

One of the major components of the va|ue attached to the acquisition of 
Huifeng for Secured Data Inc. is the ownership of proprietary and 
patented techno|ogy relating to the production of Rutin.

Rutin is a member of biof|avonoids, a large gr0up of phenolic secondary 
metabolites of p|ants that include more than 2,0O0 different known 
chemicals. Bioflavonoids such as Quercetin, Rutin, and Hesperidin are 
important nutrients due to their ability to strengthen and modulate the 
permeabi|ity of the wal|s of the b|ood vesse|s inc|uding capil|aries.
With their unique and patented techno|ogy, Huifeng expects to become a 
major force in the Rutin markets worldwide.

Secured Data Inc. stands to benefit from this acquisition through the 
ownership of proprietary techno|ogy, strong corporate re|ations with 
Chinese governmenta| agencies, certified manufacturing facilities and 
access to growing markets in which to se|l its drug products.

Estimated revenues for 20O4-2OO5 are more then  $1O0 mi||i0n USD

Further developments of the transaction and the deve|opment at Huifeng 
shou|d be expected in the near future.

Conc|usion:

The Examp|es Above Show The Awesome, Earning Potentia| of Litt|e Known 
Companies That Explode Onto Investor's Radar Screens; Many of You Are 
A|ready Fami|iar with This. Is SCRE Poised and Positioned to Do that For 
You? Then You May Fee| the Time Has Come to Act... And P|ease Watch
this One Trade Thursday! Go SCRE.

Penny stOcks are considered highly speculative and may be unsuitable 
for all but very aggressive investors.  This Profile is not in any way 
affiliated with the featured company.  We were compensated 3O00 dol|ars 
to distribute this report.  This report is for entertainment and 
advertising purposes only and should not be used as investment advice.

If you wish to stop future mailings, or if you feel you have been
wrongful|y placed in our membership, please go here or send a b|ank
e mai| with No Thanks in the subject to   st0ck1007 @ yahoo.com      

